Zura Bio Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zura Bio Limited (ZURA)

Zura Bio's October 27, 2026 SEC filing, which included a shelf registration covering up to $700 million in securities, described tibulizumab as the Company's lead product candidate being "currently advanced" in Phase 2 clinical trials. Less than two weeks later, TibuSHIELD failed to meet its primary endpoint, triggering a significant decline in ZURA's stock price.

NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Zura Bio Limited (NASDAQ: ZURA) shares fell approximately 72% at the market open on November 9, 2026 after the Company disclosed that its Phase 2 TibuSHIELD trial of tibulizumab failed to meet its Week 16 primary endpoint. The decline came less than two weeks after Zura Bio's October 27, 2026 SEC filings described tibulizumab as its lead product candidate being "currently advanced" in Phase 2 clinical trials. If you bought ZURA and are now holding a loss, you may have rights to recover it. Shareholders who suffered losses are encouraged to submit their ZURA loss details now . You may also contact Joseph E. Levi, Esq. via email at [email protected]  or by telephone at (212) 363-7500.

On October 27, 2026, Zura Bio filed a Form S-3 shelf registration statement with the SEC covering up to $700 million in securities. That total included approximately $114 million in Class A ordinary shares available for sale through an at-the-market offering. The registration statement described the Company's lead product candidate, tibulizumab, as being "currently advanc[ed]" in Phase 2 clinical trials. The same day, the Company's Form 10-Q reported increased expenditures as it continued execution of its Phase 2 clinical trials evaluating tibulizumab in adults with HS and SSc. Additionally, a Form 8-K furnishing the Company's third-quarter earnings release stated that TibuSHIELD topline data "remains on track for Q4 2026."

Then came the readout. TibuSHIELD, which enrolled 247 participants, failed to meet its primary endpoint at either dose tested. The primary endpoint measured the percentage change from baseline in total abscess and inflammatory nodule count at Week 16. The trial also failed to meet key secondary endpoints, including HiSCR50 and HiSCR75. Following the results, Zura Bio discontinued development of tibulizumab for hidradenitis suppurativa. Levi & Korsinsky is investigating potential securities law violations on behalf of Zura Bio investors.

Lost money on Zura Bio? Request a free review of your ZURA losses  or call (212) 363-7500.

WHY LEVI & KORSINSKY  -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered billions of dollars for investors.

Frequently Asked Questions About the ZURA Investigation

Q: Who is eligible to participate in the ZURA investigation?  A: Investors who purchased ZURA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did ZURA stock drop?  A: Shares fell approximately 72% at the market open on November 9, 2026 after the Company disclosed that its Phase 2 TibuSHIELD trial of tibulizumab failed to meet its Week 16 primary endpoint at either dose tested and that it would discontinue development of the drug for hidradenitis suppurativa. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?  The investigation concerns whether Zura Bio made potentially false or misleading statements about the status of its Phase 2 tibulizumab program. In particular, the investigation focuses on the Company's October 27, 2026 SEC filing, which described tibulizumab as its lead product candidate being advanced in Phase 2 clinical trials, and its accompanying statement that topline results from the TibuSHIELD study in hidradenitis suppurativa "remain[] on track for Q4 2026." On November 9, 2026, the Company disclosed that TibuSHIELD failed to meet its primary endpoint at either dose tested and that it was discontinuing development of tibulizumab for hidradenitis suppurativa.

Q: What do ZURA investors need to do right now?  A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?  A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my ZURA shares -- can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ZURA and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony?  A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP